Recruiting PHASE4 INTERVENTIONAL NCT06634641

Clozapine-related Immunodeficiency in Parkinsons Disease (CLOZIDPD)

Assessment of Clozapine-related Immunodeficiency Effect in Parkinsons Disease Patients

Sponsor: Centre Hospitalier Universitaire, Amiens

Conditions Clozapine Immunodeficiency Parkinson's Disease (PD) Psychosis

Interventions blood test

Updated 3 times since 2024 Last updated: Nov 17, 2025 Started: Oct 1, 2024 Primary completion: Sep 30, 2027 Completion: Sep 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Clozapine and Immunodeficiency and is currently actively recruiting participants. Centre Hospitalier Universitaire, Amiens leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

3 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE4
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE4
Nov 2024 — Sep 2025 [monthly]

Recruiting PHASE4

First recorded

Oct 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire, Amiens

Data source: Centre Hospitalier Universitaire, Amiens

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salouël, France